Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.
Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C; HENCORE Group. Pradat P, et al. Among authors: braconier jh. J Viral Hepat. 2007 Aug;14(8):556-63. doi: 10.1111/j.1365-2893.2006.00829.x. J Viral Hepat. 2007. PMID: 17650289
Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation.
Jönsson G, Lood C, Gullstrand B, Holmström E, Selander B, Braconier JH, Sturfelt G, Bengtsson AA, Truedsson L. Jönsson G, et al. Among authors: braconier jh. Clin Immunol. 2012 Sep;144(3):214-27. doi: 10.1016/j.clim.2012.06.008. Epub 2012 Jul 6. Clin Immunol. 2012. PMID: 22842196 Free article.
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
Pedersen C, Alsiö Å, Lagging M, Langeland N, Färkkilä M, Buhl MR, Mørch K, Westin J, Sangfelt P, Norkrans G, Christensen PB; NORDynamicIC Study Group. Pedersen C, et al. J Viral Hepat. 2011 Apr;18(4):245-51. doi: 10.1111/j.1365-2893.2010.01303.x. J Viral Hepat. 2011. PMID: 20384961 Clinical Trial.
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ. Björkander J, et al. Among authors: braconier jh. Vox Sang. 2006 May;90(4):286-93. doi: 10.1111/j.1423-0410.2006.00764.x. Vox Sang. 2006. PMID: 16635071 Clinical Trial.
Complement deficiency and disease: an update.
Sjöholm AG, Jönsson G, Braconier JH, Sturfelt G, Truedsson L. Sjöholm AG, et al. Among authors: braconier jh. Mol Immunol. 2006 Jan;43(1-2):78-85. doi: 10.1016/j.molimm.2005.06.025. Mol Immunol. 2006. PMID: 16026838 Review.
Reply.
Frey S, Dagan R, Ashur Y, Chen XQ, Ibarra J, Kollaritsch H, Mazur MH, Poland GA, Reisinger K, Walter E, Van Damme P, Braconier JH, Uhnoo I I, Wahl M, Blatter MM, Clements D, Greenberg D, Jacobson RM, Norrby SR, Rowe M, Shouval D, Simmons SS, van Hattum J, Wennerholm S, O'Brien Gress J, Chan I I. Frey S, et al. Among authors: braconier jh. J Infect Dis. 2000 Sep;182(3):1005-6. doi: 10.1086/315793. J Infect Dis. 2000. PMID: 10950808 No abstract available.
65 results